Overall verdict
Neutral
6.4/10
1-year performance
-24.06%
Score breakdown
Down 24.1% over 1 year, 37% of the 52-week range.
Strongest: Profitability 8.9/10. Weakest: Growth 2.1/10.
27 analysts, target +0.2% vs the price.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing ; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents ; point of care systems ; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay ;
rapid diagnostics lateral flow testing products ; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A ; cardiometabolic test systems ; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula ; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases ;
diabetes care products, such as glucose and blood glucose monitoring systems ; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Sector
Health Care
Industry
Health Care Equipment and Supplies
Primary listing
Nyse
United States
CEO
Robert Ford
Founded
1888
Employees
115 000
Revenue / employee
385 461 USD
Next earnings
October 14, 2026 (estimated)
Institutional holders
- BlackRock, Inc.8.66%
- VANGUARD CAPITAL MANAGEMENT LLC6.45%
- STATE STREET CORP4.59%
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC3.39%
- VANGUARD PORTFOLIO MANAGEMENT LLC2.78%
- GEODE CAPITAL MANAGEMENT, LLC2.23%
- Capital Research Global Investors2.09%
- Capital International Investors1.97%
- MORGAN STANLEY1.51%
- Other institutions44.44%
- Rest of the register21.90%
2961 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
135.45 USD
52-week low
81.97 USD
1-year performance
-24.06%
Declining
Year-to-date performance
-17.01%
Declining
Drawdown
-24.99%
Marked drawdown
Position in the 52-week range
37% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 1.6 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of September 2009 are worth today
| Abbott Laboratories | 85 161 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 1.6 times as much as the world ETF.
- Worst fall:-46 % between March 2025 and May 2026. 10,000 € placed at the top fell to 5 378 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
Abbott Laboratories earned more than the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Abbott Laboratories: 85 161 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 87.22 USD - 90.17 USD (comparables only)
The price implies growth of 6.76% per year; the company grows at 8.23%.
Gross margin 52.8%, net margin 11.6%, ROIC 7.5%, ROE 10.6%.
Net margin
11.60%
Exceptional
Sector 8.18%|S&P 12.97%
Gross margin
52.81%
Fair
Return on equity (ROE)
10.63%
Exceptional
Sector 6.97%|S&P 16.52%
Return on invested capital (ROIC)
7.50%
High
Free cash flow margin (FCF)
16.80%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.45x
High
Margin stability
7.6 pts
Uneven
Revenue to net income
Growth
2.1/10Revenue up 13.0% over 1 year, 5.1% a year over 5, EPS 8.2% a year over 5.
Revenue (trailing 12 months)
46.6Md USD
Revenue growth (1y)
13.02%
Hyper-growth
Revenue growth (3y)
1.55%
Moderate
EPS growth (1y)
-48.22%
Declining
EPS CAGR (5y)
8.23%
Fair
EPS revisions (3 months)
0.66%
Revised up
Valuation
4.7/10P/E 32.8x, forward P/E 28.8x, EV/EBITDA 16.8x, PEG 3.99. The multiple sits in the 43th percentile of its own 5-year history.
P/E (TTM)
32.8x
Fair
Sector 28.9x|S&P 23.0x
Forward P/E
28.8x
Fair
EV / EBITDA
16.8x
Fair
Sector 15.7x|S&P 14.5x
PEG
3.99
Very expensive
Sector 1.76|S&P 0.86
Fair value (reverse DCF)
88.70 USD
Overvalued
P/E vs its own 5-year history
among the 43% lowest valuations
In line with its history
Market cap
179Md USD
Financial strength
7.9/10Cash covers 17.2% of the debt, net debt/EBITDA 0.5x.
Net debt / EBITDA
0.5x
Very solid
Gearing (net debt / equity)
52.17%
Solid
Cash
5.6Md USD
Cash / market cap
3.13%
Tight
Cash / total debt
17.18%
Tight
Interest coverage
9.6x
Solid
Net debt
27.0Md USD
Equity
51.8Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 101.07 USD
- MM20105.53
- MM50106.96
- MM200104.75
- RSI 1435.1
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-2.10%
200-day average slope, 3 months
-7.13%
50-day average slope, 1 month
+5.86%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.19 % per day
Volatility change
-31.13%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 3.53 (17) | 5.52 (26) | 50 204 (27) | 12 989 (15) | 6 303 (16) |
| 2027 | 4.55 (17) | 6.07 (26) | 54 528 (27) | 14 491 (15) | 7 978 (16) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 14, 2026.
Same sub-industry: 190 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BSX | 7.0 | 7.2 | 64.7Md USD | 18.1x | 17.5 % | 7.5 % | 10.5 % | 1.8x | 5.6 % | -54.3 % | ||
| 2 | MDT | 7.0 | 7.1 | 114Md USD | 22.0x | 13.9 % | 13.7 % | 7.0 % | 2.0x | 5.4 % | -6.7 % | ||
| 3 | SYK | 6.9 | 7.5 | 105Md USD | 28.3x | 14.4 % | 9.4 % | 10.0 % | 1.7x | 4.5 % | -27.6 % | ||
| 4 | ISRG | 6.5 | 6.8 | 141Md USD | 45.6x | 28.4 % | 18.5 % | 17.4 % | -1.6x | 2.3 % | -11.4 % | ||
| 5 | ABT | 6.4 | 5.9 | 179Md USD | 32.8x | 11.6 % | 13.0 % | 7.5 % | 0.5x | 4.4 % | -24.1 % | ||
| 6 | IDXX | 6.3 | 6.4 | 41.1Md USD | 36.7x | 25.0 % | 9.7 % | 56.6 % | 0.5x | 3.0 % | -20.4 % | ||
| 7 | SHL | 6.3 | 6.5 | 47.2Md USD | 18.9x | 9.6 % | 1.8 % | 7.4 % | 2.7x | 5.4 % | -20.5 % | ||
| 8 | EW | 6.2 | 5.6 | 50.0Md USD | 51.5x | 15.0 % | 13.6 % | 8.7 % | -2.0x | 2.9 % | 15.4 % | ||
| 9 | BDX | 5.7 | 5.1 | 49.7Md USD | 55.1x | 6.2 % | 5.4 % | 3.2 % | 3.4x | 5.1 % | 22.7 % |
